NCT00818064已完成1 期
A Randomised, Double-blind, Placebo-controlled, Single- Dose, Dose-escalation Trial of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Adverse events, including injection site tolerability
研究概览
简要总结
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety and tolerability of single doses of Anti-IL-20 in healthy volunteers (HV) and patients with rheumatoid arthritis (RA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For healthy volunteers (HV) the following applies:
- •Subjects who are considered to be generally healthy based on assessment of medical history, physical examination and clinical laboratory data at screening, as judged by the Investigator
- •Females who are post-menopausal, surgically sterile or of non-child-bearing potential
- •For rheumatoid arthritis (RA) patients the following applies:
- •A diagnosis of rheumatoid arthritis according to the American College of Rheumatology (ACR1987 classification) of at least three months' duration prior to dosing
- •Active RA, characterised by a Disease Activity Score 28 (DAS28) greater than 3.2
- •Methotrexate treatment (stable doses of maximally 25.0 mg/week for at least 4 weeks) and concomitant intake of folic acid 1 mg/day or 5 mg/week
- •Females who are post-menopausal, surgically sterile or of non-child-bearing potential
排除标准
- •For healthy volunteers (HV) the following applies:
- •Male subjects who do not accept to use double barrier methods of birth control from first dosing until 3 moths after their last visit
- •Body mass index (BMI) below 18.5 or above 35.0 kg/m2
- •Clinically significant cardiac or cardiovascular disease
- •Abnormal blood pressure and heart rate
- •Hepatic insufficiency
- •Renal insufficiency
- •Positive for humane immunodeficiency virus (HIV)
- •Positive for hepatitis B (HBV) or hepatitis C (HCV)
- •Lymphoproliferative disease
- •History or signs of malignancy (except adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to dosing)
- •History of any autoimmune or current inflammatory conditions including rheumatoid arthritis or any other joint disease
- •Active or latent tuberculosis: For tuberculosis unvaccinated subjects detected as a positive Mantoux test. For subjects vaccinated against tuberculosis detected as a positive QuantiFeron-test
- •Chronic or ongoing infectious disease requiring systemic anti-infectious treatment within the last 2 weeks prior to administration of trial drug
- •Any vaccination within the last month before dosing
- •Known active viral, bacterial or fungal infection, including herpes, herpes zoster or cold sores 14 days prior to dosing
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 2 weeks prior to dosing, unless in the opinion of the Investigator the medication will not interfere with the trial procedures or compromise the safety of the subject
- •History of or current drug and/or alcohol abuse
- •Blood donation within the last 3 months (more than 0.45 L)
- •For rheumatoid arthritis (RA) patients the following applies:
- •Male subjects who do not accept to use double barrier methods of birth control from first dosing until 3 months after their last visit
- •Body mass index (BMI) below 18.5 or above 35.0 kg/m2
- •Subjects with chronic inflammatory autoimmune disease other than rheumatoid arthritis (except secondary Sjögren's syndrome)
- •History of or current inflammatory joint disease other than rheumatoid arthritis (e.g. gout, psoriatic or reactive arthritis, Lyme's disease, juvenile arthritis)
- •Chronic or ongoing infectious disease requiring systemic anti-infectious treatment within the last 2 weeks prior to dosing
- •Any vaccination within the last month before dosing
- •Known active viral, bacterial or fungal infection, including herpes, herpes zoster or cold sores 14 days prior to administration of trial product
- •Lymphoproliferative disease
- •History or signs of malignancy (except adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to dosing)
- •Use of selective cyclooxygenase-2 (COX-2) inhibitors within the last 2 weeks prior to randomisation
- •Concomitant medication
研究组 & 干预措施
C, HV
Experimental
Dose cohort 3 (3 subjects active, 1 placebo)
干预措施: placebo (Drug)
A, HV
Experimental
Dose cohort 1 (3 subjects active, 1 placebo)
干预措施: anti-IL-20 (Drug)
A, HV
Experimental
Dose cohort 1 (3 subjects active, 1 placebo)
干预措施: placebo (Drug)
B, HV
Experimental
Dose cohort 2 (3 subjects active, 1 placebo)
干预措施: anti-IL-20 (Drug)
B, HV
Experimental
Dose cohort 2 (3 subjects active, 1 placebo)
干预措施: placebo (Drug)
C, HV
Experimental
Dose cohort 3 (3 subjects active, 1 placebo)
干预措施: anti-IL-20 (Drug)
D, HV
Experimental
Dose cohort 4 (3 subjects active, 1 placebo)
干预措施: anti-IL-20 (Drug)
D, HV
Experimental
Dose cohort 4 (3 subjects active, 1 placebo)
干预措施: placebo (Drug)
E, HV
Experimental
Dose cohort 5 (3 subjects active, 1 placebo)
干预措施: anti-IL-20 (Drug)
E, HV
Experimental
Dose cohort 5 (3 subjects active, 1 placebo)
干预措施: placebo (Drug)
A, RA
Experimental
Dose cohort 1 (3 subjects active, 1 placebo)
干预措施: anti-IL-20 (Drug)
A, RA
Experimental
Dose cohort 1 (3 subjects active, 1 placebo)
干预措施: placebo (Drug)
B, RA
Experimental
Dose cohort 2 (3 subjects active, 1 placebo)
干预措施: anti-IL-20 (Drug)
B, RA
Experimental
Dose cohort 2 (3 subjects active, 1 placebo)
干预措施: placebo (Drug)
C, RA
Experimental
Dose cohort 3 (3 subjects active, 1 placebo)
干预措施: anti-IL-20 (Drug)
C, RA
Experimental
Dose cohort 3 (3 subjects active, 1 placebo)
干预措施: placebo (Drug)
结局指标
主要结局
Adverse events, including injection site tolerability
时间窗: during treatment
次要结局
- Maximum observed serum concentration (Cmax)(during treatment)
- Time to reach maximum serum concentration (tmax)(during treatment)
- Terminal serum half-life (t½)(during treatment)
- Relevant biomarkers in serum and plasma, as well as synovial fluid (if applicable)(during treatment)
- Area under the serum concentration-time curve (AUC0-t and AUC)(during treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese SubjectsHealthyDiabetesNCT01865331Novo Nordisk A/S32
已完成
1 期
First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid ArthritisInflammationRheumatoid ArthritisNCT00927927Janssen Research & Development, LLC65
已完成
2 期
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid ArthritisInflammationRheumatoid ArthritisNCT01223911Novo Nordisk A/S34
已完成
1 期
Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®Growth Hormone DisorderHealthyNCT01034202Novo Nordisk A/S56
已完成
1 期
Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid ArthritisInflammationRheumatoid ArthritisNCT01038674Novo Nordisk A/S16